Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Alemtuzumab on Work Capacity in Patients With RRMS: Pooled Analysis of CARE-MS Core Studies
Multiple Sclerosis
P12 - Poster Session 12 (12:00 PM-1:00 PM)
9-007
Evaluate the effect of alemtuzumab on work capacity in RRMS patients from the pooled CARE-MS core and extension studies.
In the CARE-MS studies (NCT00530348; NCT00548405), alemtuzumab demonstrated significantly greater efficacy versus subcutaneous interferon beta-1a (SC IFNB-1a) over 2 years (y). Efficacy was maintained through Y6 in an extension (NCT00930553).
Patients received SC IFNB-1a or 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months [M] later: 3 days) during core studies, and additional alemtuzumab as needed in the extension (12 mg/day, 3 days). Work capacity was assessed by the Health Resource Utilization questionnaire item: “Did you have to take sick leave during the past 3 months because of your MS?” Results were censored for M3 and M15 (alemtuzumab infusion days).
Of patients treated with alemtuzumab (n=811) or SC IFNB-1a (n=389), 58.6% and 60.7%, respectively, reported being employed/self-employed at baseline. During the 2-y core studies, cumulative percentages of patients taking sick leave due to MS were significantly lower with alemtuzumab versus SC IFNB-1a at all time points post-baseline (M1–6: 9.6% vs 15.9%; M1–9: 14.7% vs 23.7%; M1–12: 20.4% vs 27.2%; M1–18: 23.8% vs 33.6%; M1–21: 26.0% vs 35.6%; M1–24: 28.6% vs 39.1%; P<0.05 for all). Significantly fewer alemtuzumab-treated patients took sick leave within the past 3M versus SC IFNB-1a at M24 (6.6% vs 11.2%; odds ratio [95% CI] = 0.55 [0.34, 0.88], P=0.0129); sick leave rates remained relatively stable with alemtuzumab in the extension at M36 (7.6%), M48 (7.2%), M60 (5.6%), and M72 (5.8%). Safety will be presented.
Significantly fewer alemtuzumab-treated patients took sick leave due to MS than SC IFNB-1a–treated patients over 2y, and their rate of sick leave remained stable over 6y. Improved work capacity outcomes with alemtuzumab highlight its potential for increasing work participation in RRMS patients.
Authors/Disclosures
Brian Steingo, MD (Sunrise Medical Group)
PRESENTER 		Dr. Steingo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, EMD Serono, Bristol Myers, Sanofi, Janssen. Dr. Steingo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen, EMD Serono, Bristol Myers, Sanofi, Janssen. The institution of Dr. Steingo has received research support from Infinity Clinical Research.
Regina Berkovich, MD, PhD (Regina Berkovich MD PhD Inc) The institution of Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alexion, Biogen, Genentec, Mallincrodt, Sanofi, Novartis, . Dr. Berkovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Genentec, Sanofi, Merck . Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion, Biogen, Sanofi, Merck, Mallincrodt . The institution of Dr. Berkovich has received research support from Biogen, Sanofi, Merck.
Elisabeth G. Celius, MD Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Celius has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Celius has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
Daniel Kantor, MD, FÂ鶹´«Ã½Ó³»­ (Medical Partnership 4 MS+) Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
R.M.M. Hupperts, MD (Biogen Int. B.V.) No disclosure on file
Celia Oreja Guevara Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for viatris. Celia Oreja Guevara has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for biogen. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bms. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for jannsen.
No disclosure on file
Jennifer Wills, PA-C, MSCS No disclosure on file
David Rog, MBBS Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Rog has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Dr. Rog has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neuraxpharm. Dr. Rog has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Rog has received research support from Merck. The institution of Dr. Rog has received research support from Novartis. The institution of Dr. Rog has received research support from TG Therapeutics. Dr. Rog has received research support from Janssen-Cilag.
Miriam Ross, NP No disclosure on file
Bernard M. Uitdehaag, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Amsterdam University Medical Centers) Dr. Uitdehaag has nothing to disclose.
Zia Choudhry No disclosure on file
No disclosure on file
Lobat Hashemi No disclosure on file
Tjalf Ziemssen, MD, FÂ鶹´«Ã½Ó³»­ (University Clinic Dresden) Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS . Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Ziemssen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Ziemssen has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Dresden Internation University. The institution of Dr. Ziemssen has received research support from Novartis. The institution of Dr. Ziemssen has received research support from Merck. The institution of Dr. Ziemssen has received research support from Sanofi. The institution of Dr. Ziemssen has received research support from BMS. The institution of Dr. Ziemssen has received research support from Roche.